Post-Conference Workshop Day Wednesday October 21, 2020

WORKSHOP A

WORKSHOP A

WORKSHOP C

9:00 - 11:30

The Human Microbiome and the Immune System – The Pathway to Disease Causation?

Interactions between the immune system and the human microbiome may play a pivotal role in understanding the underlying mechanisms that dictate causation. In addition to this, there is increasing evidence which suggests that the microbiome is become a critical predictor of response to several therapeutics, including cancer immunotherapies. Despite this promise, the link between microbial populations and the immune system is still poorly understood.

Attend this workshop to gain expert insights into:

• The current research literature and translational evidence that links the human microbiome with immune system modulation across several therapeutic areas including cancer, pancreatitis and IBD

• The immune pathways that alter/or reverse the course of disease progression

• Identifying new immune-based therapeutics targets that may drive innovate therapeutic development

12:00 - 14:30

Developing Microbiome-Based Therapeutics for Infant Diseases

With a global rise in incidences of immune disorders, childhood-onset diabetes and childhood obesity, the causal link between the maternal-infant microbiome and health outcomes provides researchers with a unique window of opportunity for new products and solutions that target the early gut microbiome. Join a leading paediatric clinician and drug developer at this unique pre-conference workshop to get a deep dive into the mechanisms, challenges and opportunities when developing microbiome-targeting therapeutics during the first 1000 days of life.

Attend this workshop to gain expert insights into:

• The role of FMT for IBD in paediatric populations

• Immune-driven mechanisms that help drive infant microbiome modulation with positive health outcomes

• The unique challenges of developing microbiome-targeted therapeutics in vulnerable patient populations

• Efforts into creating preventative health tools across several diseases which have early on-set across infant populations

15:00 - 17:30

Developing Microbiome-Targeting Biomarkers & Therapeutics for Cancer  Treatment and Patient Response

Increased knowledge of the mechanisms underlying the hallmarks of cancer has driven the evolution of cancer therapeutics. More recently, a wealth of scientific evidence has demonstrated the impact of the gut microbiome in modulating response and resistance to existing cancer treatments. Additionally, findings have revealed causal and consequential roles of the microbiome in cancer pathogenesis and progression.

Attend this workshop to gain expert insights into:

• The fundamental mechanistic pathways underpinning the causality of the human microbiome in cancer and consequential effects of cancer therapeutics on microbial dysbiosis

• Recent results from clinical trials that incorporate the microbiome as a measurable endpoint

• New industry investigations from organisations who are leveraging the power of the human microbiome to develop novel therapeutic strategies that improve patient safety and efficacy outcomes

Aida Habtezion
Nikki Klatt

Aida Habtezion MD
Principal Investigator
Stanford University

Nikki Klatt
Associate Professor Paediatrics
University of Miami

Lynn Bry
Stacy Kahn1
Nurry Hong

Lynn Bry MD
Director
Massachusetts Host Microbiome Center

Stacy Kahn MD
Attending Physician
Boston Children’s Hospital

Nurry Hong
CEO
Pareto Bio

Deepak Gopalakrishnan - AstraZeneca
Jonathan Peled
Capture xan

Deepak Gopalakrishnan
Scientist - Microbiome Discovery
AstraZeneca

Jonathan Peled MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center

Xue Liang
Microbiome Scientist
Merck Exploratory Science Center